In the United States, the first aceclidine-based drug for treating age-related farsightedness has been approved — VIZZ eye drops. Presbyopia affects more than 1.8 billion people worldwide, and the new treatment promises up to 10 hours of clear near vision after a single use.
Developed by LENZ Therapeutics, the drops work by gently constricting the pupil and creating a “pinhole effect” — like a camera, when depth of field increases and the image becomes sharp. This makes it possible to focus on nearby objects without glasses. Unlike previous solutions, VIZZ does not affect the accommodative muscles, minimizing the risk of side effects.
Its efficacy and safety have been confirmed in three clinical studies covering more than 30,000 days of use without complications. VIZZ is expected to reach U.S. pharmacies by the end of 2025, opening a new approach to vision correction for people over 45. And the image of a grandmother in glasses may change forever: she will be able to read a book to her grandchild without searching for her glasses all over the apartment.
